ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
2024년 고중성지방혈증(TG)을 동반한 고비중지단백질 C(LDL-C) 총 유병자 수는 128,720,003명으로 추정되며, 2029년에는 총 유병자 수가 133,846,798명으로 증가할 것으로 예측됩니다.
시판 중인 고지혈증 치료제의 대부분은 효소 억제제이며, 혁신 분자와 제네릭 분자를 포함합니다.
고지혈증 치료제로 개발 중인 분자는 총 207개 품목이 있으며, 이 중 15개 품목은 등록 전 단계, 28개 품목은 임상 3상, 23개 품목은 임상 2상 단계에 있습니다.
지난 10년간 총 1,637건의 고지혈증 임상시험이 시작되었습니다. 고지혈증 임상시험이 가장 많이 진행된 해는 2023년 227건, 2022년 178건으로 그 뒤를 이었습니다.
고지혈증 치료제 개발은 남미에서는 라이선스 계약이 주류를 이루었지만, 아프리카에서는 제휴가, 아시아태평양에서는 인수가 더 활발하게 이루어졌습니다.
세계의 고지혈증 시장에 대해 조사 분석했으며, 질환 개요, 임상시험 동향, 파이프라인 개요, 향후 전망 등의 정보를 전해드립니다.
목차
제1장 목차
제1장 서문
제2장 주요 조사 결과
제3장 질병 상황
질환 개요
역학 개요
치료 개요
제4장 출시 약제 평가
주요 출시 약제
작용기전별 개요
분자 유형별 개요
제품 프로파일과 매출 예측
제5장 가격 설정과 상환 평가
연간 치료비
가격 설정과 상환까지 시간
제6장 파이프라인 약제 평가
중기에서 후기 단계 파이프라인 약제
개발 단계별 개요
작용기전별 개요
분자 유형별 개요
약제 고유의 상전이 성공률(PTSR)과 승인 가능성(LoA)
치료 분야와 적응증별 PTSR과 LoA
제7장 임상시험 평가
역사적 개요
상별 개요
상황별 개요
진행중 및 계획중인 시험의 상별 개요
가상 컴포넌트 시험
지역별 시험 개요
지역별 단일국 및 다국간 시험
상별 스폰서 상위 20개사
상황별 스폰서 상위 20개사
엔드포인트 상황별 개요
인종과 민족별 개요
등록 데이터
임상시험 실시 시설 상위 20개국
세계의 상위 20개 사이트
실현 가능성 분석 - 지역적 개요
실현 가능성 분석 - 벤치마크 모델
제8장 거래 상황
지역별 합병, 인수, 전략적 제휴
최근의 합병, 인수, 전략적 제휴
제9장 상업적 평가
제10장 향후 시장 성장 촉진요인
제11장 부록
ksm
영문 목차
영문목차
This reports provides a data-driven overview of the current and future competitive landscape in Hyperlipidemia therapeutics.
GlobalData epidemiologists estimate 128,720,003 total prevalent cases of high low-density lipoprotein C (LDL-C) with high triglycerides (TG) in 2024, which is expected to increase to 133,846,798 total prevalent cases in 2029.
Most of the marketed hyperlipidemia assets, including both innovator molecules and generic molecules, are enzyme inhibitors,
A total of 207 molecules are in development for hyperlipidemia, including 15 drugs in the pre-registration stage, 28 in Phase III, and 23 in Phase II.
A total of 1,637 clinical trials were initiated for hyperlipidemia in the last 10 years. The year with the most trials conducted for hyperlipidemia was 2023, with 227 trials, followed by 2022 with 178 trials.
In the development of hyperlipidemia assets, licensing agreements were the dominant deal type in South America, while partnerships prevailed in Africa and acquisitions were more common in the Asia-Pacific region.
Scope
GlobalData's Hyperlipidemia: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Hyperlipidemia market.
Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Hyperlipidemia market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Table of Contents
1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Molecule Type
4.4 Product Profiles and Sales Forecast
5 Pricing and Reimbursement Assessment
5.1 Annual Cost of Therapy
5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
6.1 Mid-to-late-stage Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Mechanism of Action
6.4 Overview by Molecule Type
6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.6 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Overview of Trials by Geography
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis - Geographic Overview
7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
